Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells

Leukemia & Lymphoma
M J RobertsonJ Ritz

Abstract

Murine monoclonal antibody (mAb) 7C11 binds to the same cell surface epitope as anti-APO-1 and anti-Fas and reacts specifically with cells transfected with a cDNA encoding the human Fas antigen. Furthermore, incubation with 7C11 causes death of hematopoietic cell lines that express APO-1/Fas but not APO-1/Fas-negative cell lines. 7C11 therefore recognizes the human APO-1/Fas (CD95) antigen, a 40 to 50 kDa cell surface glycoprotein that can trigger apoptosis or programmed cell death. Expression of APO-1/Fas antigen by normal and neoplastic hematopoietic cells was determined by flow cytometry using 7C11. APO-1/Fas is expressed by approximately 30 to 40% of resting peripheral blood T cells, B cells, and monocytes and by approximately 5% of resting NK cells and thymocytes. It was not detected on granulocytes, erythrocytes, or platelets. Approximately 80 to 90% of activated T cells, B cells, and thymocytes express APO-1/Fas, as do the majority of activated NK cells. Perturbation of APO-1/Fas by 7C11 does not affect the viability of resting lymphocytes or monocytes. In contrast, activated T cells and NK cells undergo apoptosis within 3 hours of exposure to 7C11. Other mAb that stimulate T cells or NK cells do not cause rapid inductio...Continue Reading

References

Feb 1, 1979·International Journal of Cancer. Journal International Du Cancer·R HurwitzJ Kersey
Nov 1, 1992·Clinical and Experimental Immunology·B M FoxwellM Feldmann
May 1, 1992·Research in Immunology·V F Quesniaux
May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P ShawJ Costa
Jan 1, 1992·Annual Review of Immunology·J J CohenK S Sellins
Apr 1, 1991·European Journal of Immunology·E VivierP Anderson
Mar 3, 1990·Lancet·K M DebatinP H Krammer
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N KobayashiS Yonehara
Jan 1, 1991·Annual Review of Immunology·P L Cohen, R A Eisenberg
Nov 1, 1990·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J W Larrick, S C Wright
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A AlcoverE L Reinherz
Dec 21, 1989·Nature·Y J LiuI C MacLennan
Oct 1, 1989·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S B Mizel
Nov 23, 1989·The New England Journal of Medicine·J E GroopmanD T Scadden
Sep 1, 1987·The Journal of Experimental Medicine·J H KehrlA S Fauci
Jun 5, 1987·Science·S C Clark, R Kamen
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J DrappaK B Elkon

❮ Previous
Next ❯

Citations

Oct 11, 2005·Autoimmunity Reviews·Antonella IsgròFernando Aiuti
May 21, 1998·Leukemia Research·T AhmedN G Abraham
Dec 17, 2002·Experimental Hematology·Faris Q B AlenziMyrtle Y Gordon
Jul 2, 1999·Experimental Hematology·G DallalioR T Means
Jan 27, 1998·Hematology/oncology Clinics of North America·O P VeibyH R Snodgrass
Sep 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emmanuelle PasseguéIrving L Weissman
Apr 14, 2004·The Journal of Experimental Medicine·Stephan MathasBernd Dörken
Jun 4, 1997·Journal of the National Cancer Institute·O MicheauM T Dimanche-Boitrel
Oct 7, 2004·Journal of the National Cancer Institute·Sameek RoychowdhuryMichael A Caligiuri
Mar 23, 2005·The Journal of Reproduction and Development·Ken KusakabeYasuo Kiso
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·C ZhangS F Schlossman
Aug 15, 2003·Leukemia & Lymphoma·Quan ChenAlexandru Almasan
Nov 8, 2001·Leukemia & Lymphoma·T H LandowskiW S Dalton
Dec 7, 2000·Cancer Investigation·N DoninJ Leibovici
Aug 21, 2001·The Journal of Investigative Dermatology·R R BullaniL E French
May 14, 2009·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Florian C KurschusNediljko Budisa
Jul 15, 2004·International Immunopharmacology·Syunji MizunoeMasaru Nasu
Nov 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F G QueG J Gores
Apr 25, 2000·Oncogene·M SchröterE Reichmann
Nov 20, 2002·Anti-cancer Drugs·Katerina DvorakovaRobert T Dorr
Aug 10, 2000·The Journal of Biological Chemistry·R DattaD Kufe
Mar 10, 2006·The Journal of Biological Chemistry·Hélène Hernandez-PigeonGuy Laurent
Feb 10, 1998·International Journal of Cancer. Journal International Du Cancer·M J Martinez-LorenzoM A Alava
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sara JalecoNaomi Taylor
May 6, 2021·Cancers·Etienne Leveille, Nathalie A Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.